Roche and Biogen Idec's ocrelizumab looks positive in Phase II for RRMS
This article was originally published in Scrip
Executive Summary
Roche and Biogen Idec's humanised anti-CD20 monoclonal antibody ocrelizumab has achieved positive results in a 220-patient Phase II study for the treatment of relapsing-remitting multiple sclerosis (RRMS), top-line data show.